Biweekly Endocrinology video recap covering regulatory actions, clinical progress, data releases, and partnerships across global markets. Themes include new approvals and launches, late-stage readouts, AI-enabled tools, and precision-medicine initiatives.
🎯 Watch Our Video Summary Capturing Endocrinology News from the Last Two Weeks
Dive deeper
🗓️ Explore weekly details and sources
- Week 27 January–2 February 2026
- Week 3 –9 February 2026
📚 See the full Endocrinology archive on our research hub pag
Top Stories Covered in This Video
Chapters
0:00 Introduction
0:09 China approves Sciwind Biosciences Xianyida for type 2 diabetes
0:29 FDA clears Phase 3 program for pilavapadin in DPNP
1:02 $4.7M AI closed-loop insulin project, UVA–CU Anschutz–UCSF collaboration
1:37 BioMed X and Government of Barbados launch DKD precision initiative
2:08 Eli Lilly’s Mounjaro, tirzepatide, now available in New Zealand after Medsafe priority review
2:31 Dexcom Stelo adds AI nutrition logging and personalized insights
2:55 Novo Nordisk CagriSema tops Ozempic in head-to-head T2D trial, REIMAGINE 2
3:31 Roche unveils Accu-Chek SmartGuide predictive CGM in Kuwait, Saudi Arabia, and Qatar
3:58 How to reach us
Transcript
Welcome to the latest edition of Endocrinology updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.
China has approved Sciwind’s Xianyida for type 2 diabetes. The world’s largest adult diabetes population now has another incretin option, entering a crowded market with major global players already active. Expect competitive pressure that could influence pricing and formulary access.
In the United States, the FDA has cleared a Phase 3 path for pilavapadin in diabetic peripheral neuropathic pain. Following an end-of-Phase 2 meeting, the program will run two 12-week, placebo-controlled trials at 10 mg daily. Phase 2b showed pain reduction versus placebo using ADPS as the primary endpoint. With no objections from the agency, prescriber choice and payer reviews may shift as full data emerge.
A $4.7 million multicenter effort led by University of Virginia with CU Anschutz and UCSF aims to advance fully closed-loop insulin delivery. Backed by Breakthrough T1D and Helmsley, and supported in kind by Tandem and Arecor, the project will develop adaptive algorithms paired with ultra-rapid insulin to reduce the burden of meal and exercise inputs. Study design and control of confounders will determine how practice and reimbursement interpret outcomes.
BioMed X and the Government of Barbados have launched a precision project focused on early diabetic kidney disease in Barbadian patients with type 2 diabetes. Supported by an EU PharmaNext call, the team plans an AI driven “digital African twin” approach to biomarker discovery and stratified therapy. This signals upstream pipeline investment and modality expansion in an underrepresented population.
Access developments continue in Oceania. Eli Lilly reports that Mounjaro, tirzepatide, is now available in New Zealand for obesity and type 2 diabetes after Medsafe priority review. Label specifics were not detailed. Availability could affect local pricing dynamics and placement on formularies.
On the consumer technology front, Dexcom’s Stelo platform adds AI powered nutrition logging, a food database, meal tracking, and personalized daily insights with a nationwide rollout. By linking glucose data to everyday metabolic choices, these features may streamline initiation, adherence, and remote prescribing workflows.
Novo Nordisk’s CagriSema, the cagrilintide plus semaglutide combination, topped Ozempic in the Reimagine 2 head-to-head trial in type 2 diabetes over 68 weeks. Reported results show greater HbA1c reduction, minus 1.91 versus minus 1.76, and greater weight loss, 14.2 percent versus 10.2 percent, both statistically significant. Pending full data, these deltas could influence treatment ladders and payer negotiations.
Roche has unveiled Accu-Chek SmartGuide, an AI predictive CGM solution in the Middle East. It forecasts glucose trends from 30 minutes ahead to overnight, with availability reported in Kuwait, Saudi Arabia, and Qatar. Officials in the UAE highlight potential public health value, with the goal of reducing stress and improving adherence through anticipatory guidance.
Stay ahead in endocrinology research! Like, share, and subscribe for weekly updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time.
Why it matters
- GLP-1/GIP competition intensifies across regions, shifting access and pricing dynamics.
- AI-enabled insulin delivery and CGM aim to reduce burden and improve adherence.
- Precision projects in underrepresented populations target earlier DKD detection and tailored therapy.
- Head-to-head outcomes may reframe GLP-1 combo positioning in T2D treatment ladders.
🗓️ Explore weekly details and sources
- Week 27 January–2 February 2026
- Week 3 –9 February 2026
📚 See the full Endocrinology archive on our research hub pag
FAQ
What is Xianyida and where is it approved?
Xianyida is Sciwind Biosciences’ type 2 diabetes therapy, now approved in China per company statement reported by Reuters [1].
What did the FDA allow for pilavapadin?
FDA raised no objections to a Phase 3 program for pilavapadin in DPNP, including two 12-week, placebo-controlled studies at 10 mg daily with ADPS as the primary endpoint [2].
Who is funding the UVA closed-loop insulin project and what is the aim?
Breakthrough T1D and Helmsley fund the ~$4.7M project, aiming for adaptive, fully closed-loop insulin delivery using ultra-rapid insulin (endpoint not specified) [3].
What is the BioMed X Barbados initiative targeting?
Early diabetic kidney disease in Barbadian T2D patients, using molecular profiling and an AI “digital African twin” for biomarker-guided stratification [4].
Is Mounjaro available in New Zealand and under what pathway?
Yes, Eli Lilly says Mounjaro is available following Medsafe priority review, for obesity and type 2 diabetes (label specifics not stated) [5].
How is CagriSema performing versus Ozempic in T2D?
In REIMAGINE 2, CagriSema showed greater HbA1c reduction and weight loss versus Ozempic over 68 weeks, with statistical significance reported [7].
Entities / Keywords
Sciwind Biosciences; Xianyida; GLP-1; China.
Lexicon Pharmaceuticals; pilavapadin (LX9211); DPNP; FDA; ADPS.
University of Virginia; CU Anschutz; UCSF; Breakthrough T1D; Helmsley; Tandem; Arecor; closed-loop insulin.
BioMed X; Government of Barbados; EU PharmaNext; diabetic kidney disease; digital African twin.
Eli Lilly; tirzepatide; Mounjaro; Medsafe; New Zealand.
Dexcom; Stelo; CGM; AI nutrition logging; consumer metabolic health.
Novo Nordisk; CagriSema; semaglutide; cagrilintide; Ozempic; REIMAGINE 2.
Roche; Accu-Chek SmartGuide; Middle East; predictive CGM.